Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143

Cancer Research

Volumn 63, Issue 7, 2003, Pages 1527-1533

  Li, Yin ^a   Raffo, Anthony J ^a   Drew, Lisa ^a   Mao, Yuehua ^a   Tran, Andy ^a   Petrylak, Daniel P ^a   Fine, Robert L ^a  

^a Coll Phys/Surgs of Columbia Univ ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALANINE DERIVATIVE; CASPASE 3; CASPASE 8; FAS ANTIBODY; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; MUTANT PROTEIN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN FAP 1; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ASSAY; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TEMPERATURE DEPENDENCE; TEMPERATURE SENSITIVE MUTANT; WILD TYPE;

ADENOCARCINOMA; ALANINE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME ACTIVATION; FAS LIGAND PROTEIN; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MUTATION; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037379914     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Friend, S. p53: a glimpse at the puppet behind the shadow play. Science (Wash. DC), 265: 334-335, 1994.
2. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Wash. DC), 253: 49-53, 1991.
3. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Wash. DC), 265: 346-355, 1994.
4. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
5. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
6. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
7. Woods, D. B., and Vousden, K. H. Regulation of p53 function. Exp. Cell Res., 264: 56-66, 2001.
8. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
9. Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
10. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
11. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., Kruzel, E., and Radinsky, R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 15: 3032-3040, 1995.
12. Yonehara, S., Ishii, A., and Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med., 169: 1747-1756, 1989.
13. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature (Lond.), 364: 806-809, 1993.
14. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M., FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 81: 505-512, 1995.
15. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., and Wallach, D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem., 270: 7795-7798, 1995.
16. Stanger, B. Z., Leder, P., Lee, T. H., Kim, E., and Seed, B. RIP: a novel protein containing a death domain that interacts with Fas/APO-I (CD95) in yeast and causes cell death. Cell, 81: 513-523, 1995.
17. Caelles, C., Helmberg, A., and Karin, M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature (Lond.), 370: 220-223, 1994.
18. Wu, J. K., Ye, Z., and Darras, B. T. Frequency of p53 tumor suppressor gene mutations in human primary brain tumors. Neurosurgery, 33: 824-830, 1993.
19. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
20. Daujat, S., Neel, H., and Pierre, J. Preferential expression of mdm2 oncogene during the development of neural crest and its derivatives in mouse early embryogenesis. Mech. Dev, 103: 163-165, 2001.
21. Friedlander, P., Haupt, Y., Prives, C., and Oren, M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol., 16: 4961-4971, 1996.
22. Zhang, W., Guo, X. Y., Hu, G. Y., Liu, W. B., Shay, J. W., and Deisseroth, A. B. A temperature-sensitive mutant of human p53. EMBO J., 13: 2535-2544, 1994.
23. Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., and Krammer, P. H. p53 activates the CD95 (APO-I/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med., 188: 2033-2045, 1998.
24. Barak, Y., Juven, T., Haffner, R., and Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J., 12: 461-468, 1993.
25. 1 checkpoint control. Cell, 82: 675-684, 1995.
26. Momand, J., Wu, H. H., and Dasgupta, G. MDM2-master regulator of the p53 tumor suppressor protein. Gene (Amst.), 242: 15-29, 2000.
27. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Investig., 99: 403-413, 1997.
28. Tamura, T., Aoyama, N., Saya, H., Haga, H., Futami, S., Miyamoto, M., Koh, T., Ariyasu, T., Tachi, M., and Kasuga, M. Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene, 11: 1939-1946, 1995.
29. Miyake, H., Hara, I., Gohji, K., Arakawa, S., and Kamidono, S. p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. Int. J. Oncol., 12: 469-473, 1998.
30. Egle, A., Villunger, A., Marschitz, I., Kos, M., Hittmair, A., Lukas, P., Grunewald, K., and Greil, R. Expression of Apo-1/Fas (CD95). Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. Br. J. Haematol., 97: 418-428, 1997.
31. Fuchs, E. J., McKenna, K. A., and Bedi, A. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32β. Cancer Res., 57: 2550-2554, 1997.
32. Pirollo, K. F., Bouker, K. B., and Chang, E. H. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs, 11: 419-432, 2000.
33. Wang, Y., Blandino, G., Oren, M., and Givol, D. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene, 17: 1923-1930, 1998.
34. Fan, J., and Bertino, J. R. Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Mol. Pharmacol., 56: 966-972, 1999.
35. Inoue, A., Narumi, K., Matsubara, N., Sugawara, S., Saijo, Y., Satoh, K., and Nukiwa, T. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett., 157: 105-112, 2000.
36. Das, G. C., Holiday, D., Gallardo, R., and Haas, C. Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition. Cancer Lett., 165: 147-153, 2001.
37. Stewart, Z. A., Tang, L. J., and Pietenpol, J. A. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene, 20: 113-124, 2001.
38. Makin, G., and Hickman, J. A. Apoptosis and cancer chemotherapy. Cell Tissue Res., 301: 143-152, 2000.